Education
About Us
Working with TipRanks
Follow Us
Zyus Life Sciences Corporation (TSE:ZYUS)
:ZYUS
Total Valuation
ZYUS Life Sciences has a market cap or net worth of C$36.48M. The enterprise value is ―.
Market CapC$36.48M
Enterprise Value―
Share Statistics
ZYUS Life Sciences has 58,589,170 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding58,589,170
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ZYUS Life Sciences’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count55
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of ZYUS Life Sciences is ―. ZYUS Life Sciences’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, ZYUS Life Sciences had revenue of ― and earned -42.59M in profits. Earnings per share was ―.
Revenue―
Gross Profit171.00K
Operating Income-19.15M
Pretax Income―
Net Income-42.59M
EBITDA-42.06M
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
ZYUS Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.24
52-Week Price Change-42.31%
50-Day Moving Average0.76
200-Day Moving Average0.84
Relative Strength Index (RSI)13.61
Average Volume (3m)12.07K
Important Dates
ZYUS Life Sciences upcoming earnings date is May 28, 2025, TBA Not Confirmed.
Last Earnings DateApr 30, 2025
Next Earnings DateMay 28, 2025
Ex-Dividend Date―
Financial Position
ZYUS Life Sciences as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, ZYUS Life Sciences has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
ZYUS Life Sciences EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
ZYUS Life Sciences has ― in cash and marketable securities with 7.94M in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt7.94M
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for ZYUS Life Sciences is C$1.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$1.50
Price Target Upside123.88% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―